Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Supplemental material
  • Version history
  • Article usage
  • Citations to this article
Advertisement

ResearchIn-Press PreviewMuscle biologyNeuroscience Open Access | 10.1172/jci.insight.203215

PGC-1α pathway dysregulation disrupts myofiber specification in a mouse model of SBMA

Curtis J. Kuo,1 Laura B. Chopp,2 Zhigang Yu,1 Luhan Ni,3 Hien T. Zhao,4 Janghoo Lim,5 and Andrew P. Lieberman1

1Department of Pathology, University of Michigan Medical School, Ann Arbor, United States of America

2University of Michigan Medical School, Ann Arbor, United States of America

3Department of Genetics, Yale University School of Medicine, New Haven, United States of America

4Neuroscience, Ionis Pharmaceuticals, Inc., Carlsbad, United States of America

5Department of Neuroscience, Yale University School of Medicine, New Haven, United States of America

Find articles by Kuo, C. in: PubMed | Google Scholar

1Department of Pathology, University of Michigan Medical School, Ann Arbor, United States of America

2University of Michigan Medical School, Ann Arbor, United States of America

3Department of Genetics, Yale University School of Medicine, New Haven, United States of America

4Neuroscience, Ionis Pharmaceuticals, Inc., Carlsbad, United States of America

5Department of Neuroscience, Yale University School of Medicine, New Haven, United States of America

Find articles by Chopp, L. in: PubMed | Google Scholar

1Department of Pathology, University of Michigan Medical School, Ann Arbor, United States of America

2University of Michigan Medical School, Ann Arbor, United States of America

3Department of Genetics, Yale University School of Medicine, New Haven, United States of America

4Neuroscience, Ionis Pharmaceuticals, Inc., Carlsbad, United States of America

5Department of Neuroscience, Yale University School of Medicine, New Haven, United States of America

Find articles by Yu, Z. in: PubMed | Google Scholar

1Department of Pathology, University of Michigan Medical School, Ann Arbor, United States of America

2University of Michigan Medical School, Ann Arbor, United States of America

3Department of Genetics, Yale University School of Medicine, New Haven, United States of America

4Neuroscience, Ionis Pharmaceuticals, Inc., Carlsbad, United States of America

5Department of Neuroscience, Yale University School of Medicine, New Haven, United States of America

Find articles by Ni, L. in: PubMed | Google Scholar |

1Department of Pathology, University of Michigan Medical School, Ann Arbor, United States of America

2University of Michigan Medical School, Ann Arbor, United States of America

3Department of Genetics, Yale University School of Medicine, New Haven, United States of America

4Neuroscience, Ionis Pharmaceuticals, Inc., Carlsbad, United States of America

5Department of Neuroscience, Yale University School of Medicine, New Haven, United States of America

Find articles by Zhao, H. in: PubMed | Google Scholar

1Department of Pathology, University of Michigan Medical School, Ann Arbor, United States of America

2University of Michigan Medical School, Ann Arbor, United States of America

3Department of Genetics, Yale University School of Medicine, New Haven, United States of America

4Neuroscience, Ionis Pharmaceuticals, Inc., Carlsbad, United States of America

5Department of Neuroscience, Yale University School of Medicine, New Haven, United States of America

Find articles by Lim, J. in: PubMed | Google Scholar |

1Department of Pathology, University of Michigan Medical School, Ann Arbor, United States of America

2University of Michigan Medical School, Ann Arbor, United States of America

3Department of Genetics, Yale University School of Medicine, New Haven, United States of America

4Neuroscience, Ionis Pharmaceuticals, Inc., Carlsbad, United States of America

5Department of Neuroscience, Yale University School of Medicine, New Haven, United States of America

Find articles by Lieberman, A. in: PubMed | Google Scholar

Published May 7, 2026 - More info

JCI Insight. https://doi.org/10.1172/jci.insight.203215.
Copyright © 2026, Kuo et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published May 7, 2026 - Version history
View PDF
Abstract

Skeletal muscle pathology is a critical but poorly understood contributor to neuromuscular degeneration in spinal and bulbar muscular atrophy (SBMA), a CAG/polyglutamine (polyQ) expansion disorder caused by mutation in the androgen receptor (AR). Using a gene-targeted SBMA mouse model, we applied single-nucleus RNA sequencing to identify a disease-specific population of skeletal muscle myonuclei that replaced normal myonuclear subtypes. This transition was associated with dysregulation of the pathway governed by PGC-1α, a central regulator of myofiber specification and metabolic identity. PGC-1α dysfunction in SBMA muscle was age-, hormone-, and polyQ length–dependent and was partially rescued by subcutaneous delivery of AR-targeted antisense oligonucleotides. Integrated ChIP-seq and RNA-seq analyses revealed that aberrant PGC-1α activity promoted the expression of a distinct set of myofiber specification genes while downregulating those that define healthy Type IIb and Type IIx myonuclei. We propose a model in which this dysfunction arose downstream of polyQ-mediated sequestration of PGC-1α cofactors MEF2, CREB, and CBP, leading to transcriptional reprogramming and cellular dysfunction. These findings implicated PGC-1α dysregulation as a key event linking AR polyQ expansion to skeletal muscle degeneration and suggested a shared mechanism for polyQ-mediated muscle pathology across related neurodegenerative diseases.

Supplemental material

View Unedited blot and gel images

View

View Sup table 1

View Sup table 2

View Sup table 3

View Sup table 4

View Sup table 5

View Sup table 6

View Sup table 7

View Sup table 8

View Publication license from BioRender

Version history
  • Version 1 (May 7, 2026): In-Press Preview

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Supplemental material
  • Version history
Advertisement
Advertisement

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts